Abstract:AbstractActive inflammation is an important feature of vulnerable plaques, and monocyte chemoattractant protein‐1 (MCP‐1) is a key chemokine that promotes monocyte–endothelium binding and initiates inflammation. We aimed to determine whether dominant‐negative mutation of MCP‐1 could reverse atherosclerotic lesion progression and prevent vulnerable plaques from rupture regardless of serum lipid levels. The mutant MCP‐1 was produced by deletion of the N‐terminal amino acids 2 to 8 (7ND), and a eukaryotic expression vector plRES‐EGFP‐7ND was constructed. The transwell chamber was used to assay chemotaxis of monocytes in vitro. Thirty New Zealand white rabbits underwent balloon‐induced abdominal aortic endothelial injury and were randomly divided into control group without gene intervention (group A, n = 10), plRES‐EGFP‐7ND treatment group (group B, n = 10) and empty vector treatment group (group C, n = 10). All rabbits were fed a diet of 1% cholesterol for 8 weeks, and then group A rabbits were killed, whereas groups B and C rabbits received an intramuscular injection of plRES‐EGFP‐7ND and an empty lipofectamine, respectively, and remained on a high cholesterol diet for 4 weeks. At the end of week 12, groups B and C rabbits underwent pharmacological triggering by injection with Chinese Russellis viper venom and histamine. Serum lipids and inflammatory markers were measured, and high‐frequency ultra‐sonography and intravascular ultrasound imaging were performed. Immunohistochemistry and RT‐PCR were used to examine expression of inflammatory markers in the plaques. In vitro transfection of plRES‐EGFP‐7ND resulted in a significant inhibition of monocyte chemotaxis (P < 0.05) and in vivo transfection of plRES‐EGFP‐7ND significantly increased the thickness of the fibrous caps and decreased plaque vulnerability index. The incidence of plaque rupture in group B was 0% as compared with 56% in the empty vector treatment group (P< 0.05). The serum levels and expression of inflammatory markers were significantly reduced in group B. In conclusion, PIRES‐EGFP‐7ND transfection effectively inhibits plaque inflammation, reverses plaque progression and prevents vulnerable plaques from rupture. These therapeutic effects are independent of serum lipid levels and demonstrate that inhibition of plaque inflammation alone without lipid lowering can stabilize vulnerable plaques.

[Roles of Monocyte Chemoattractant Protein-1, RANTES and Fractalkine on Promoting Vulnerability of Atherosclerotic Plaques].

Role of Chemokines in Promoting Instability of Coronary Atherosclerotic Plaques and the Underlying Molecular Mechanism

Monocyte-Chemoattractant Protein-1 Levels in Human Atherosclerotic Lesions Associate With Plaque Vulnerability

Assessment of RANTES levels as the indicators of plaque vulnerability in rabbit models of atherosclerosis.

Relationship Between Cytokines and Angina Pectoris and Its Risk Factors

Circulating Cd36 and Fractalkine Levels Are Associated with Vulnerable Plaque Progression in Patients with Unstable Angina Pectoris

Local Gene Silencing of Monocyte Chemoattractant Protein-1 Prevents Vulnerable Plaque Disruption in Apolipoprotein E-Knockout Mice

Changes in plasma monocyte chemoattractant protein-1 in patients with acute coronary syndrome and patients with restenosis after angioplasty

Relationship Between Hs-Crp, Prommp-1, TIMP-1 and Coronary Plaque Morphology: Intravascular Ultrasound Study

Peripheral blood markers in detection of vulnerable coronary atherosclerotic plaque

Lower AMP-activated Protein Kinase Level is Associated with the Vulnerability of Coronary Atherosclerotic Plaques by Attenuating the Expression of Monocyte Autophagy

The Role of Atherosclerotic Plaque Stability and Inflammation in the Pathogenesis of Acute Coronary Syndrome

Study on Atherosclerotic Plaque Composition in Patients with Intermediate Coronary Stenosis by Multidetector Computed Tomography Angiography,serum Matrix Metalloproteinase 9 and Soluble CD40 Ligand

[Associations Between the Plasma Inflammatory Markers and Plaque Morphologies of Coronary Artery Lesions].

[A Correlation Study of Serum Inflammatory Factors and Intravascular Ultrasound Features of Atherosclerotic Plaques in Patients with Angina Pectoris].

The Role of Monocyte Chemotactic Protein-Induced Protein 1 (MCPIP1) in Angiotensin II-induced Macrophage Apoptosis and Vulnerable Plaque Formation.

Characteristic of peripheral blood monocyte subsets and chemokines in early stage of acute coronary syndrome

Changes of circulating fractalkine in patients with acute coronary syndroms

The Plasma Concentration of Monocyte Chemoattractant Protein-1 and Clinical Significance in Patients with Premature Heart Disease

Dominant‐negative Mutation of Monocyte Chemoattractant Protein‐1 Prevents Vulnerable Plaques from Rupture in Rabbits Independent of Serum Lipid Levels

miR-532-3p-CSF2RA Axis as a Key Regulator of Vulnerable Atherosclerotic Plaque Formation